Compare MMSI & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MMSI | IDYA |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.5B |
| IPO Year | 1996 | 2019 |
| Metric | MMSI | IDYA |
|---|---|---|
| Price | $91.55 | $36.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 16 |
| Target Price | ★ $98.88 | $52.86 |
| AVG Volume (30 Days) | ★ 1.1M | 728.9K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.93 | ★ 61.90 |
| EPS | ★ 1.33 | N/A |
| Revenue | ★ $1,515,906,000.00 | $218,710,000.00 |
| Revenue This Year | $8.85 | N/A |
| Revenue Next Year | $5.88 | $201.05 |
| P/E Ratio | $68.50 | ★ N/A |
| Revenue Growth | 11.75 | ★ 3024.43 |
| 52 Week Low | $59.74 | $23.23 |
| 52 Week High | $94.75 | $40.58 |
| Indicator | MMSI | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 84.65 | 55.76 |
| Support Level | $79.09 | $33.57 |
| Resistance Level | $94.75 | $37.82 |
| Average True Range (ATR) | 2.87 | 1.34 |
| MACD | 0.79 | -0.02 |
| Stochastic Oscillator | 95.53 | 67.07 |
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.